THE BIO-KING REPORT: SLDB
Fintel reports that on June 24, 2024, Leerink Partners upgraded their
outlook for Solid Biosciences (
NasdaqGS:SLDB) from
Market Perform to
Outperform.
Analyst Price Forecast Suggests 160.53% Upside
As of June 12, 2024, the average one-year
price target for Solid Biosciences is 16.83. The forecasts range from a
low of 12.12 to a high of $21.00. The average price target represents an increase of 160.53%
All of this does not tell the whole story though:
1- Shares of Solid Bio spent two years in free fall from early 2021 to late 2023.
2- Chasing SRPT: William Blair analyst Tim Lugo says Solid Bio could be a fast follower in Duchenne muscular dystrophy.
Sarepta Therapeutics(
SRPT) has the only approved gene therapy on the market for the disease, which primarily affects boys and causes progressive muscle weakness.
3-Solid Bio's drug works by helping a patient's body make a miniature version of the dystrophin protein. Dystrophin keeps muscles intact, but it's missing in patients with Duchenne muscular dystrophy. In mice, Solid Bio's gene therapy led to high levels of dystrophy expression.
"Given the 100% expression viewed in several areas of the mouse model, we believe expression data should be strong, and if the safety profile is clean, we would expect this to be a catalyst for shares to
spike severalfold," Lugo said.
4- Now when this analyst was talking about severalfold (great word) Solid was $13. // We are now getting it for much less.. sEveralfold from $13..
.= $36//<--- GBA TARGET***
Solid Bio is working on a treatment for catecholaminergic polymorphic ventricular tachycardia, or CPVT. This inherited disorder causes sudden heart rhythm disturbances, also called arrhythmias, in healthy children.
CPVT is "a potentially even larger driver of value than DMD given the company's lead position in this deadly disease that impacts 20,000 people in the United States alone," he said. "Solid's program also holds several possibilities for fast-to-market clinical trial design."
<<< Alright all of that is well and good but there's more...
A) We just joineD the Russell 3000
B) FDA's Sarepta decision 'positive' for gene therapy, STATNews reports » 06/21 SRPT, SLDB<-----
C) Piper sees opportunity for Solid Biosciences after broad Elevidys approval » 06/21 SLDB, SRPT<------
D) Solid Biosciences expects cash to fund strategic priorities into 2026 » 05/15 SLDB
E) Pfizer had a setback in this same field... and that ignited SRPT...
Sarepta gains after Pfizer’s late-stage setback for Duchenne therapy
NewsThu, Jun. 13
F) Pfizer DMD gene therapy miss paves way for Sarepta, Solid Biosciences, says Citi » 06/13 SRPT, SLDB, PFE
Ok so SRPT already fired /// SLDB is up next.... (Hopefully)
I will be buying Solid this Monday or Tues.
